Skip to main content
RDY
NYSE Life Sciences

Dr. Reddy's Q1 FY27: Semaglutide Charge Obscures Strong Base Business

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$12.19
Mkt Cap
$10.444B
52W Low
$12.185
52W High
$15.67
52W Position info
0.0% above low
Off High info
22% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

RDY is trading near its 52-week low of $12.185 (0.0% above the low).

Summary

A ₹190 Cr semaglutide API charge hit Dr. Reddy's Q1 FY27 reported profits, but the underlying base business grew double digits across all regions with a 15.4% EBITDA margin ex-impact.


Key Events · Earnings and Guidance · RDY

  • Semaglutide API Charge Hits Q1

    A ₹190 Cr charge for semaglutide API inventory provision and associated costs dragged the reported EBITDA margin to 12.5%, down from 15.4% ex-impact.

  • Base Business Delivers Double-Digit Growth

    Excluding the semaglutide impact, revenues grew across all segments: North America +35% YoY, India +17%, Emerging Markets +31%, and Europe +13%.

  • Strong Balance Sheet

    As of June 30, 2026, a net cash surplus of ₹5,027 Cr provides ample liquidity to navigate the semaglutide supply disruption.

  • Regulatory Overhang Persists

    A Form 483 with 7 observations was received at the biologics facility in June 2026; the company has responded within the timeline.


Analysis · RDY · Life Sciences

A ₹190 Cr semaglutide API charge dragged Dr. Reddy's reported Q1 FY27 EBITDA margin to 12.5%, but stripping out that one-time hit reveals a healthy 15.4% margin on double-digit revenue growth across all geographies. The previously flagged quality issue has now materialized financially, yet the underlying generics engine is performing well—North America grew 35% YoY, India 17%, and Emerging Markets 31%. The company maintains a strong net cash position of ₹5,027 Cr. The market will need to weigh the temporary semaglutide setback against the broad-based operational strength.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RDY was trading at $12.19 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.4B. The 52-week trading range was $12.19 to $15.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RDY - Latest Insights

RDY
Nov 05, 2026, 6:06 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $14.75
Real-time Price: $14.79 info
Change: +$0.040 (+0.27%) info
Market Cap: $12.251B info
RDY
Nov 03, 2026, 1:09 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $14.38
Real-time Price: $14.79 info
Change: +$0.414 (+3%) info
Market Cap: $12.251B info
RDY
Nov 02, 2026, 12:25 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $14.10
Real-time Price: $14.79 info
Change: +$0.695 (+5%) info
Market Cap: $12.251B info
RDY
Oct 23, 2026, 12:22 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $13.22
Real-time Price: $14.79 info
Change: +$1.57 (+12%) info
Market Cap: $12.251B info
RDY
Oct 14, 2026, 12:43 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $12.82
Real-time Price: $14.79 info
Change: +$1.97 (+15%) info
Market Cap: $12.251B info